NASDAQ: PMCB - PharmaCyte Biotech, Inc.

Rentabilité sur six mois: -25.29%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions PharmaCyte Biotech, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.

plus de détails
The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2010-09-17
ISIN US71715X2036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://pharmacyte.com
Цена ао 1.49
Changement de prix par jour: 0% (1.27)
Changement de prix par semaine: +5.39% (1.205)
Changement de prix par mois: -19.62% (1.58)
Changement de prix sur 3 mois: -15.33% (1.5)
Changement de prix sur six mois: -25.29% (1.7)
Changement de prix par an: -40.09% (2.12)
Evolution du prix sur 3 ans: -43.05% (2.23)
Evolution du prix sur 5 ans: +3 635.29% (0.034)
Evolution des prix depuis le début de l'année: -20.63% (1.6)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0.514 10
P/E 60.86 1
EV/EBITDA -89.49 0
Total: 3.63

Efficacité

Nom Signification Grade
ROA, % 0.5012 1
ROE, % 0.5949 1
Total: 0.3333

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0.0212

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -98.14 0
Rentabilité Ebitda, % -108.78 0
Rentabilité EPS, % -1344.13 0
Total: 0
Plus de détails

Établissements Volume Partager, %
K2 Principal Fund, L.P. 304613 0.01
Geode Capital Management, LLC 215637 0.01
Vanguard Group Inc 171335 0.01
Equitec Proprietary Markets LLC 82727 0
Sabby Management, LLC 82373 0
Renaissance Technologies, LLC 38100 0
Dimensional Fund Advisors LP 29307 0
Blackrock Inc. 28769 0
Citadel Advisors Llc 28618 0
Schonfeld Strategic Advisors LLC 23200 0



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Joshua N. Silverman Interim CEO, Interim President & Interim Chairman 197.92k 1970 (55 années)
Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer 380k 1958 (67 années)
Dr. Jose L. Iglesias M.D. Consulting Chief Medical Officer N/A 1957 (68 années)
Dr. Hans-Peter Hammes Member of Medical & Scientific Advisory Board and Consultant N/A

Adresse: United States, Las Vegas. NV, 3960 Howard Hughes Parkway - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://pharmacyte.com